October 4th - 6th, New York
Harnessing the exquisite specificity of the immune system to detect and attack cancer cells has long been a dream of cancer immunologists. Cancer vaccines are getting ever closer to becoming reality as they are shown to consistently and reproducibly stimulate the immune system to attack cancer-specific targets. Now early-phase clinical trials are beginning to show hints of the promise of immunotherapy.
WHAT: New findings in the development of cancer vaccines from the USA, Australia, Europe and Japan will be presented as part of the International Cancer Immunotherapy Symposia Series.
WHEN: October 4-6, 2004
WHERE: Manhattan Conference Center at the Millenium Broadway Hotel 145 West 45th Street, New York.
WHO: Organized by the Cancer Research Institute, New York. Speakers are drawn from the international Cancer Vaccine Collaborative, leading US academic groups, and industry efforts. Over 250 scientists and physicians registered so far.
ONLINE: Registration and more information at: www.cancerresearch.org. Registration not required for journalists/writers with press accreditation.
Identification and characterization of cancer-specific immunological targets (antigens) for different tumor types. Analysis and clinical monitoring of immune response to cancer antigens. Vaccine formulation and development in academia and industry, including the use of heat-shock proteins and pox viruses. Early-phase clinical trials results in melanoma and ovarian cancer.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
It is common sense to take a method and try it; if it fails, admit it frankly and try another. But above all, try something.
-- Franklin D. Roosevelt